Literature DB >> 9764783

The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection.

A Cozzi Lepri1, T L Katzenstein, H Ullum, A N Phillips, P Skinhøj, J Gerstoft, B K Pedersen.   

Abstract

OBJECTIVE: It has been suggested that the plasma HIV RNA level is a better predictor of AIDS and death than the CD4 lymphocyte count. We assessed whether the prognostic value of plasma virus levels was different according to the CD4 count.
DESIGN: Prospective cohort study of HIV-infected patients followed for a median of 2.91 years (range, 0.02-4.54).
SETTING: Department of Infectious Diseases at Rigshospitalet, Copenhagen, Denmark. PARTICIPANTS: A group of 255 HIV-infected individuals with an initial measurement of CD4 lymphocyte count and plasma HIV RNA. MAIN OUTCOME MEASURE: Survival time.
RESULTS: The plasma HIV RNA (median 101410 copies/ml; range (range 200-7200000) and the CD4 lymphocyte count (median 250 cells x 10(6)/l; range 1-1247) were negatively correlated (Pearson r = -0.53; P < 0.00001). Of the 255 patients, 110 died during follow-up. Overall, a higher HIV RNA level was associated with increased risk of death, but the association was smaller in patients with lower CD4 lymphocyte counts (test for interaction P < 0.0001). In patients with CD4 count below 50 cells x 10(6)/l the association between HIV RNA and risk of death was not statistically significant (relative hazard per 10-fold higher HIV RNA level was 1.53; P = 0.11; adjusted for age and CD4 count) while that between the CD4 count and risk of death was highly significant (relative hazard per 50% lower CD4 count 1.38; P = 0.005; adjusted for age and HIV RNA level).
CONCLUSIONS: Patients were relatively lightly treated with antiretroviral drugs both before and during this study. In this situation, it appears that the HIV RNA level has a relatively weak association with risk of death in patients with advanced HIV infection and that the CD4 lymphocyte count is probably more useful in assessing prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764783     DOI: 10.1097/00002030-199813000-00011

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

Authors:  Andrew M Hill; Kelly Gebo; Lindsay Hemmett; Mickael Löthgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Change over time of mortality predictors after HAART initiation in a Senegalese cohort.

Authors:  Pierre De Beaudrap; Jean-François Etard; René Ecochard; Assane Diouf; Allé Baba Dieng; Vannina Cilote; Ibrahima Ndiaye; Ndèye Fatou Ngom Guèye; Pape Mandoumbé Guèye; Papa Salif Sow; Souleymane Mboup; Ibra Ndoye; Eric Delaporte
Journal:  Eur J Epidemiol       Date:  2008-01-16       Impact factor: 8.082

3.  Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression.

Authors:  Lindi Roberts; Jo-Ann S Passmore; Carolyn Williamson; Francesca Little; Lisa M Bebell; Koleka Mlisana; Wendy A Burgers; Francois van Loggerenberg; Gerhard Walzl; Joel F Djoba Siawaya; Quarraisha Abdool Karim; Salim S Abdool Karim
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

4.  Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)?

Authors:  Lionel Piroth; Christine Binquet; Marielle Buisson; Evelyne Kohli; Michel Duong; Michèle Grappin; Michal Abrahamowicz; Catherine Quantin; Henri Portier; Pascal Chavanet
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

5.  Impact of age on markers of HIV-1 disease.

Authors:  Vanessa Pirrone; David J Libon; Christian Sell; Chad A Lerner; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

6.  Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women.

Authors:  Elizabeth R Brown; Phelgona Otieno; Dorothy A Mbori-Ngacha; Carey Farquhar; Elizabeth M Obimbo; Ruth Nduati; Julie Overbaugh; Grace C John-Stewart
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

7.  HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.

Authors:  Philippa C Matthews; Emily Adland; Jennifer Listgarten; Alasdair Leslie; Nompumelelo Mkhwanazi; Jonathan M Carlson; Mikkel Harndahl; Anette Stryhn; Rebecca P Payne; Anthony Ogwu; Kuan-Hsiang Gary Huang; John Frater; Paolo Paioni; Henrik Kloverpris; Pieter Jooste; Dominique Goedhals; Cloete van Vuuren; Dewald Steyn; Lynn Riddell; Fabian Chen; Graz Luzzi; Thambiah Balachandran; Thumbi Ndung'u; Søren Buus; Mary Carrington; Roger Shapiro; David Heckerman; Philip J R Goulder
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

8.  Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa.

Authors:  Mhairi Maskew; A Patrick Macphail; Denise Whitby; Matthias Egger; Carole L Wallis; Matthew P Fox
Journal:  Infect Agent Cancer       Date:  2011-11-17       Impact factor: 2.965

9.  Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques.

Authors:  Abdelkrim Mannioui; Olivier Bourry; Pierre Sellier; Benoit Delache; Patricia Brochard; Thibault Andrieu; Bruno Vaslin; Ingrid Karlsson; Pierre Roques; Roger Le Grand
Journal:  Retrovirology       Date:  2009-11-23       Impact factor: 4.602

10.  Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.

Authors:  Eline L Korenromp; Brian G Williams; George P Schmid; Christopher Dye
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.